New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
06:44 EDTPBYIPuma Biotechnology price target raised to $27 from $20 at Leerink
Leerink raised its price target for Puma Biotechnology citing the company's progress in advancing neratinib. The firm keeps an Outperform rating on the stock.
News For PBYI From The Last 14 Days
Check below for free stories on PBYI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
07:12 EDTPBYIPuma Biotechnology neratinib use unlikely to be limited, says Citigroup
Although Puma's Neratinib breast cancer drug was enriched for high risk HER2+ patients during a recent trial, Citigroup does not expect its use to be restricted to high risk women. The firm keeps a $292 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use